Peptide API Liraglutide/Liraglutide acetate CAS 204656-20-2 CAS NO.204656-20-2

MSDS/COA Download

Min.Order Quantity:: 1 Gram

Purity:: 98% Min

Port:: hangzhou

Payment Terms:: T/T,MoneyGram

Add to Inquiry Cart

Product Details

Keywords

Liraglutide supplier, peptide hormone
Liraglutide acetate
Liraglutide manufacturer

Quick Details

ProName: Peptide API Liraglutide/Liraglutide ac...
CasNo: 204656-20-2
Molecular Formula: C172H265N43O51
Appearance: White powder
Application: pharmaceutical ingredients ,research c...
DeliveryTime: Within 3-5days
PackAge: According client's requirements
Port: hangzhou
ProductionCapacity: 200 Gram/Day
Purity: 98% Min
Storage: keep sealed and keep from direct light
Transportation: According client's requirements
LimitNum: 1 Gram
Moisture Content: NML8.0%
Impurity: NML2.0%

Superiority

our advantages:

1.product capacity: eptidego has produced thousands of peptides ranging in quantity from milligrams to multiple kilograms with purities up to 99.0%.

2. samples free trial: our company welcome samples to test our quality then make regular orders.

3. good service: the company have 24 hours online service and feedback to our clients ontime

4. quality guarantee: we have strict quality control system before our delivery and refunds or re-deliver if any quality problems.

5. fast delivery and safe shipping: the compnay process orders in time and have much experienced in internation shipping, always keep goods safe shipping and fast delivery.

Details

about liraglutide/liraglutide acetate cas 204656-20-2

name	liraglutide/liraglutide acetate
synonyms	nn 2211; nnc 90-1170; victoza
cas no.	204656-20-2
molecular formula	c172h265n43o51
molecular weight	3751.20
appearance	white powder
purity	99% min

liraglutide (nn2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone glp-1 that stimulates insulin secretion. marketed under the brand name victoza, it is an injectable drug developed by novo nordisk for the treatment oftype 2 diabetes. in 2015, novo nordisk began marketing it in the u.s. and e.u. under the brand name saxenda as a treatment for adults, who are obese or overweight with at least one weight-relatedcomorbid condition.

usage

liraglutide is a once-daily injectable derivative of the human incretin (metabolic hormone) glucagon-like peptide-1 (glp-1), for the treatment of type 2 diabetes or obesity.

test	specification	result
appearance	white powder	conforms
ms	3751.3±1.0	conforms
related substances （purity）	unspecified impurity for each impurity: nmt1.0% total impurity: nmt 2.0%	0.29%(single largest impurity) 1.18%
acetic acid	nmt 8.0%	0.5%
water content(karl fischer）	nmt 7.0%	4.8%
peptide content(n%)	nlt80%	94.5%